|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
Q2 FY2013
As of Jun 30, 2013
|
Q1 FY2013
As of Mar 31, 2013
|
Q4 FY2012
As of Dec 31, 2012
|
Q3 FY2012
As of Sep 30, 2012
|
Q2 FY2012
As of Jun 30, 2012
|
Q1 FY2012
As of Mar 31, 2012
|
Q4 FY2011
As of Dec 31, 2011
|
Q3 FY2011
As of Sep 30, 2011
|
Q2 FY2011
As of Jun 30, 2011
|
Q1 FY2011
As of Mar 31, 2011
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||
| Current assets | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Restricted cash | |||||||||||||||||
| Accounts receivable, net of allowance for doubtful accounts of $5,571 (2014 — $4,867) | |||||||||||||||||
| Rebates receivable | |||||||||||||||||
| Other current assets | |||||||||||||||||
| Inventory | |||||||||||||||||
| Deferred income taxes | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Property and equipment, net of accumulated depreciation of $161,038 (2014 — $144,220) | |||||||||||||||||
| Goodwill | |||||||||||||||||
| Other intangible assets, net of accumulated amortization of $611,562 (2014 — $574,503) | |||||||||||||||||
| Deferred income taxes | |||||||||||||||||
| Other long-term assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| LIABILITIES AND EQUITY | |||||||||||||||||
| Current liabilities | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Customer deposits | |||||||||||||||||
| Deferred revenue | |||||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||||
| Rebates payable | |||||||||||||||||
| Current portion - long-term debt | |||||||||||||||||
| Pharmacy benefit claims payable | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Deferred income taxes | |||||||||||||||||
| Long term debt | |||||||||||||||||
| Long-term debt | |||||||||||||||||
| Other long-term liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Shareholders’ equity | |||||||||||||||||
| Common shares: no par value, unlimited shares authorized; 208,012,259 shares issued and outstanding at March 31, 2015 (December 31, 2014 — 207,493,541 shares) | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Retained earnings | |||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||
| Total shareholders' equity | |||||||||||||||||
| Non-controlling interest | |||||||||||||||||
| Total equity | |||||||||||||||||
| Total liabilities and equity | |||||||||||||||||
Loading...
